Loading...
Market
What will be the first indication for Myricx Pharma's NMTi-ADC therapeutics in clinical trials by end of 2024?
2
Resolution / Starting Odds
Breast cancer • 25%
Lung cancer • 25%
Colorectal cancer • 25%
Other • 25%
Official announcements from Myricx Pharma or clinical trial registries
Story
London-Based Myricx Pharma Raises £90 Million in 2024 Series A for Cancer Drug Development
Jul 8, 2024, 05:42 AM
British biotech spinout Myricx Pharma, based in London, has successfully raised £90 million ($115 million) in a series A financing round in 2024. The funding, which is one of the largest in recent years in the UK, includes contributions from investors such as the controlling shareholder of Ozempic maker Novo Nordisk and SofinnovaVC. The capital will be utilized to advance Myricx's novel N-myristoyltransferase (NMT) inhibitor antibody-drug conjugates (NMTi-ADC) therapeutics into clinical development. CEO Robin Carr highlighted the company's innovative NMT payload approach to ADCs. This significant investment underscores the growing interest and commitment to cancer treatment advancements.
View original story
Similar markets
Lung Cancer • 25%
Breast Cancer • 25%
Colorectal Cancer • 25%
Other • 25%
Lung cancer • 25%
Breast cancer • 25%
Colorectal cancer • 25%
Other • 25%
Mesothelioma • 25%
Lung Cancer • 25%
Breast Cancer • 25%
Other • 25%
Phase 1 • 33%
Phase 2 • 33%
Phase 3 • 33%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%
Trial halted • 25%
Limited efficacy • 25%
Moderate efficacy • 25%
High efficacy • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Positive results • 50%
Negative results • 50%
Therapeutic use in hospitals • 25%
Research tool for labs • 25%
No commercial application • 25%
Other • 25%